- Home
- ETON vs NATH Comparison
ETON vs NATH Comparison
Compare ETON & NATH Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | ETON | NATH |
|---|---|---|
| Founded | 2017 | 1916 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Restaurants |
| Sector | Health Care | Consumer Discretionary |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 498.8M | 397.6M |
| IPO Year | 2018 | N/A |
Fundamental Metrics
Financial Performance| Metric | ETON | NATH |
|---|---|---|
| Price | $15.92 | $95.12 |
| Analyst Decision | Strong Buy | |
| Analyst Count | 3 | 0 |
| Target Price | ★ $29.67 | N/A |
| AVG Volume (30 Days) | ★ 277.8K | 50.8K |
| Earning Date | 11-06-2025 | 11-06-2025 |
| Dividend Yield | N/A | ★ 2.10% |
| EPS Growth | N/A | ★ 4.02 |
| EPS | N/A | ★ 5.56 |
| Revenue | $70,316,000.00 | ★ $154,991,000.00 |
| Revenue This Year | $113.27 | N/A |
| Revenue Next Year | $36.70 | N/A |
| P/E Ratio | ★ N/A | $17.13 |
| Revenue Growth | ★ 102.77 | 7.82 |
| 52 Week Low | $11.09 | $75.15 |
| 52 Week High | $23.00 | $118.50 |
Technical Indicators
Market Signals| Indicator | ETON | NATH |
|---|---|---|
| Relative Strength Index (RSI) | 40.84 | 48.31 |
| Support Level | $16.13 | $88.67 |
| Resistance Level | $17.19 | $96.50 |
| Average True Range (ATR) | 0.75 | 3.17 |
| MACD | 0.10 | 0.88 |
| Stochastic Oscillator | 29.84 | 75.56 |
Price Performance
Historical ComparisonAbout ETON Eton Pharmaceuticals Inc.
Eton Pharmaceuticals Inc is a United States based specialty pharmaceutical company. The company is engaged in developing and commercializing pharmaceutical products to fulfill an unmet patient need. It has four commercial rare disease products, Alkindi Sprinkle for the treatment of adrenocortical insufficiency; Carglumic Acid for the treatment of hyperammonemia, Betaine Anhydrous for the treatment of homocystinuria; and Nitisinone for the treatment of hereditary tyrosinemia type 1 (HT-1). The Company has three additional product candidates in late-stage development: ET-400, ET-600, and ZENEO hydrocortisone autoinjector.
About NATH Nathan's Famous Inc.
Nathan's Famous Inc is an owner of fast food franchises in the United States. The company's reportable segment includes the Branded Product Program, Product licensing, Restaurant operations and Corporate. Branded Product Program derives revenue principally from the sale of hot dog products either directly to foodservice operators or to various foodservice distributors who resell the products to foodservice operators. It generates maximum revenue from the Branded Product Program segment. Geographically, it derives a majority of revenue from the United States.